Natixis Vir Biotechnology, Inc. Transaction History

Natixis

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$19.08 - $26.7 $1.86 Million - $2.61 Million	-97,616 Reduced 86.65%	15,043 $383,000
Q1 2022 May 13, 2022	BUY	$21.19 - $40.01 $640,128 - $1.21 Million	30,209 Added 36.64%	112,659 $2.9 Million
Q4 2021 Feb 14, 2022	SELL	$30.97 - $54.03 $730,675 - $1.27 Million	-23,593 Reduced 22.25%	82,450 $3.45 Million
Q3 2021 Nov 12, 2021	BUY	$34.9 - $54.54 $3.7 Million - $5.78 Million	106,043 New	106,043 $4.62 Million
Q2 2021 Aug 13, 2021	SELL	$38.75 - $51.0 $6.71 Million - $8.83 Million	-173,110 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$26.34 - $83.07 $252,916 - $797,638	-9,602 Reduced 5.26%	173,110 $8.88 Million
Q4 2020 Feb 12, 2021	BUY	$25.51 - $43.38 $4.66 Million - $7.93 Million	182,712 New	182,712 $4.89 Million

219

87.4M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $922M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.